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1. Introduction 
High-grade gliomas are the most prevalent and lethal form of primary intracranial tumors. 
Despite significant progress in surgical and adjuvant therapeutic treatments for gliomas, 
patient prognosis still remains dismal. The ability of gliomas to invade the normal 
surrounding brain tissue contributes to their capacity to evade therapeutic interventions, 
ultimately leading to tumor recurrence and subsequent disease progression (Rich & Bigner, 
2004).  Another major therapeutic obstacle comes from the high degree of intratumoral 
cellular heterogeneity.  The tumor mass is comprised of both terminally differentiated cells, 
cells that exhibit finite capabilities of self-renewal and multipotency, and a smaller 
subpopulation of cells that exhibit stem cell-like qualities. These stem-like cells, termed 
Glioma Initiating Cells (GICs), exihibit pluripotency, self-renewal and, importantly, are 
capable of repopulating the original parental tumor. Therefore, more effective therapies may 
be derived from targeting both the infiltrative nature of gliomas and GICs (Louis, 2006; Park 
& Rich, 2009). 
The ability of glioma tumor cells to infiltrate the normal surrounding brain tissue is a 
property that is restricted to intracranial tumors that are phenotypically glial within the 
central nervous system (CNS). As metastatic tumor cells that are highly invasive in the 
periphery fail to invade surrounding brain tissue once within the confines of the CNS, and 
invasive glioma tumors that originate in the brain rarely metastasize outside of the CNS. 
These findings suggest that the unique interaction between glioma tumor cells and the 
neural extracellular environment mediate glioma invasion (Bellail et al., 2004; Nutt et al., 
2001a).  
A defining attribute of the neural extracellular environment is the unique composition of the 
neural extracellular matrix (ECM), which unlike other peripheral matrices has low levels of 
fibrilliar proteins like collagens, fibronectin, and laminin (Ruoslahti, 1996). In both neural 
development and pathogenesis, the neural ECM regulates key biological processes 
including cellular migration, maturation, synapse formation, and plasticity. In the adult 
brain the composition of the neural ECM is largely inhibitory to cellular reorganization 
(Galtrey & Fawcett, 2007; Zimmermann & Dours-Zimmermann, 2008). Therefore, glioma 
tumor cell invasion into the normal surrounding brain tissue is derived from their ability to 
overcome this normally inhibitory extracellular environment. Decades of research has 
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demonstrated that glioma tumor cells are capable of remodeling the neural extracellular 
space by changing the expressions of proteins involved in intercellular and extracellular 
interactions. Glioma tumor cells also secrete proteases that cleave the adult neural ECM and 
temporary produced glioma ECM to create a permissive extracellular environment 
supportive of tumor cell invasion (Viapiano & Matthews, 2006). In addition, recent studies 
have determined that the expressions of several constituents of the neural ECM are enriched 
in the GIC subpopulation (Gunther et al., 2008; Phillips et al., 2006), suggesting that 
components of the neural ECM may facilitate the stem cell-like qualities of these cells by 
creating a permissive extracellular niche. 
Targeting either the expression of proteins that mediate intercellular or extracellular 
interactions or the proteases responsible for the cleavage and turnover of these proteins 
represent potential therapeutic avenues that require further exploration.  This chapter will 
focus on the role of the neural ECM, proteolytic cleavage, and alterations that occur in 
proteins that mediate intercellular interactions to facilitate glioma tumorigenicity and 
invasion and their therapeutic potential. 
2. The neural extracellular matrix in normal and developing brain 
2.1 The neural extracellular matrix 
During both neurodevelopment and in several neuropathologies, the neural ECM and 
molecular determinants of cell-ECM and cell-cell interactions regulate key biological 
processes including cellular migration, maturation, differentiation, and synapse formation 
(Hartmann & Maurer, 2001). The composition of the neural ECM largely dictates the 
permissive or inhibitory properties of the neural extracellular environment, creating a 
permissive environment favoring cell migration and process outgrowth during 
development and a notoriously inhibitory environment in the mature CNS. The neural ECM 
is capable of undergoing dynamic remodeling resulting from alterations in both the 
expression levels of ECM components and alterations in proteolytic processing 
(Zimmermann & Dours-Zimmermann, 2008). 
2.2 The composition of the neural extracellular matrix in normal brain 
The composition of the neural ECM, while most similar to cartilage, is unique and 
distinguishes the neural extracellular environment from that of other tissues and organs. 
The neural ECM is chiefly comprised of Hyaluronic Acid (HA), a repeating sugar 
disaccharide, proteoglycans and glycoproteins, which through their interactions organize 
the extracellular space of the CNS (Delpech & Delpech, 1984). The neural ECM accounts for 
ten to twenty percent of the total volume of the mature brain and occupies an even larger 
percentage in the developing brain (Ruoslahti, 1996). Unlike peripheral matrices, the neural 
ECM has low levels of fibrillar proteins including laminin, collagens, and fibronectin with 
the majority of these proteins being localized to substructures of the CNS including 
basement membranes, the subpial space, blood vessels, and in white matter tracts (Liesi, 
1984). Instead, the backbone of the neural ECM is HA, a non-sulfated glycosaminoglycan 
made up of alternating glucuronic acid and N-acetylglucosamine disaccharide subunits and 
devoid of a protein core (Ruoslahti, 1996; Toole, 2000, 2004). HA  is produced and secreted 
by hyaluronan synthases located at the surface of the cellular plasma membrane, recent 
evidence suggests that HA synthases may also play a role in tethering HA  to the cellular 
surface to facilitate its interactions with other components of the neural ECM (DeAngelis, 
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1999; Itano & Kimata, 2002; Weigel et al., 1997; Spicer & McDonald, 1998; Spicer & Tien, 
2004). 
Since HA forms the backbone of the neural matrix, proteins that organize and bind HA to 
the cell surface are particularly important for defining neural ECM structure and function. 
In many peripheral tissues the best studied HA receptor is CD44 but it is expressed at low 
levels in the adult CNS.  Instead, the major HA binding proteins expressed in the CNS are 
the lectican family members of chondroitin sulfate proteoglycans (CSPGs), also called 
hyalectans, which include versican, aggrecan, and brain-specific neurocan, and Brain 
Enriched Hyaluronan Binding protein (BEHAB)/brevican (B/b) (Bandtlow & Zimmermann, 
2000; Ruoslahti, 1996; Yamaguchi, 2000). Additionally, the HA Proteoglycan binding Link 
Proteins (HAPLNs) work in concert with lecticans to mediate HA binding (Spicer et al., 
2003). CSPGs are glycosylated proteins that are decorated with chondroitin sulfate 
glycosaminoglycan (CS-GAG) chains. The number and sulfation of CS-GAG chains varies 
for individual proteoglycans and can modulate their functions and interactions with ligands 
(Maeda, 2010). 
The structure and molecular interactions of lecticans in the normal brain has been reviewed 
thoroughly in previous publications and therefore is not included here, however, the model 
structure of the neural matrix and the position and interactions of lecticans in this matrix is 
shown in Figure 1 (Ruoslahti, 1996; Viapiano & Matthews, 2006; Yamaguchi, 2000). A 
complete understanding of the molecular interactions and functions of lecticans in the 
normal brain is, however, challenging. This is due in large part to the production of several 
protein isoforms resulting from alternative splicing, which causes a vast and 
microheterogeneous array of protein products (Viapiano et al., 2003, 2005; Dours-
Zimmerman & Zimmerman, 1994). Adding to this complexity, different protein isoforms 
from the same gene are expressed in specific temporal and regional patterns (Milev et al., 
1998; Seidenbecher et al., 1998). In addition, all lecticans are cleaved by A Disintegrin And 
Metalloproteinase with Thrombospondin Motifs (ADAMTS) and Matrix Metalloproteinase 
(MMPs) family members (Westling et al., 2004; Matthews et al., 2000). Finally the 
glycosylation of lecticans is extremely microheterogeneous and specific glycoforms can be 
expressed in a very anatomically distinct and precise manner in the normal CNS (Matthews 
et al., 2002). The molecular heterogeneity as well as the distinct spatial and temporal 
expression patterns of ECM components dictates the broad functional impact the neural 
ECM has over the CNS in both the physiological and pathophysiological state. 
2.3 The function of the neural extracellular matrix 
The neural ECM regulates a diverse array of functions in both the developing and mature 
CNS. During neurodevelopment the ECM has been shown to play a role in cell migration, 
process outgrowth, cell fate decisions, synaptogenesis and regulating cortical plasticity 
(Bandtlow & Zimmermann, 2000; Berardi et al., 2004; Frischknecht & Seidenbecher, 2008; 
Maeda et al., 2010). The composition of the ECM during neurodevelopment is largely 
permissive and favorable for cellular migration and process outgrowth (Zimmermann & 
Dours-Zimmermann, 2008). The expressions of certain lectican isoforms that aid in cellular 
movement and process outgrowth are also elevated and undergo increased proteolytic 
cleavage, which enables the turnover of ECM components to facilitate cellular migration. In 
fact, the proteolytic activities of certain proteases have been shown to be critical for normal 
development to proceed (Ethell & Ethell, 2007). As the mature synaptic circuitry is 
established the composition of the neural ECM changes to aid in stabilizing these 
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Fig. 1. Schematic Diagram of the Neural Extracellular Matrix. Diagram demonstrates the 
model composition of the ECM and cell-surface receptors in the normal adult brain (A) and 
the changes in the extracellular environment in gliomas (B). Arrows represent activation of 
signaling cascades. 
connections, creating the notoriously inhibitory extracellular environment of the adult CNS 
(Galtrey & Fawcett, 2007). The expression of HA is substantially reduced and lectican family 
members and their specific isoforms that are inhibitory to extracellular reorganization 
appear (Frischknecht & Seidenbecher, 2008; Margolis et al., 1975). Often disorders and 
diseases that affect the CNS are accompanied by alterations in the composition of the neural 
ECM, which facilitates the pathophysiological condition by modifying the extracellular 
environment (Galtrey & Fawcett, 2007; Zimmermann & Dours-Zimmermann, 2008). 
3. Extracellular matrix in brain tumors 
3.1 The neural matrix facilitates glioma tumor cell invasion 
While the extracellular environment of the mature CNS is notably resistant to plasticity and 
cellular dynamics that favor reorganization, glioma cells are capable of overcoming this 
inhibition to invade into the normal surrounding brain tissue. The invasive attributes of 
glioma cells leads to tumor cell dispersion and highly diffuse tumor-stromal boundaries, 
making complete surgical removal of tumor cells nearly impossible and tumor recurrence 
almost inevitable (Nakada et al., 2007). Brain tumor cell invasion into the normal 
surrounding brain tissue is a property that is restricted to tumors that are phenotypically 
glial and located within the CNS environment. Both non-glial tumors that originate in the 
CNS and tumors of non-neuroepithelial origin that metastasize to the CNS fail to invade the 
surrounding brain tissue, typically exhibiting well-defined brain-tumor boundaries (Bellail 
et al., 2004). Furthermore, gliomas rarely infiltrate the vasculature of the CNS and 
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disseminate outside of the nervous system environment (Kleihues et al., 1993, 2002; Bellail et 
al., 2004). The ability of glioma cells to invade the mature CNS strongly suggests that the 
unique interaction between these tumors and the extracellular neural environment is critical 
in this invasive process. The unique composition of the neural ECM defines the extracellular 
environment of the CNS and, therefore, the unique ability of glioma cells to interact with the 
neural ECM is a critical component of their invasiveness. Consistent with this hypothesis is 
work from a number of labs demonstrating that glioma tumor cells synthesize and secrete a 
specialized composition of ECM components and cell adhesion molecules that facilitate this 
interaction leading to tumor cell invasion (Bellail et al., 2004; Gladson, 1999). 
The composition of the ECM produced by glioma cells closely resembles that during early 
neurodevelopment, as both the expression levels and presence of specific protein isoforms 
predominately expressed during neurodevelopment are overrepresented in the ECM of 
gliomas. As in several invasive and metastatic tumors, the synthesis of HA is dramatically 
increased in glioma along with HA receptors CD44 and RHAMM which mediate aspects of 
glioma invasion (Delpech et al., 1993; Kuppner et al., 1992; Merzak et al., 1994; Okada et al., 
1996; Park et al., 2008; Radotra & McCormick, 1997). The expression of several lectican 
family members and their isoforms that are predominately expressed during early nervous 
system development and promote cellular reorganization are also upregulated in human 
glioma tumors. Exemplary to this are the elevated expressions of versican ( Paulus et al., 
1996), B/b (Jaworski et al., 1996), neurocan (Rauch,  2004), and Receptor Protein Tyrosine 
Phosphatase   (RPTP, also known as RPTP) (Norman et al., 1998; Peles et al., 1998). A 
specific model of a lectican isoform that is highly expressed during neurodevelopment and 
reappears in glioma tumors is a variant of B/b, B/bg. The B/bg form of brevican is 
expressed for a short developmental window in normal human brain spanning from 16 
gestational weeks to one year of age. The expression of the B/bg isoform reemerges in 
human glioma tumors causing it to be expressed in a tumor-specific manner within the 
adult CNS (Viapiano et al., 2005). Additionally, unlike normal adult ECM, the tumoral ECM 
contains traditional fibrillar matrix proteins like laminin and fibronectin, which have been 
shown to bind to proteoglycans to enhance tumor cell motility (Hu et al., 2008; Zheng et al., 
2004). While the expressions of typical fibrillar proteins are low in the extracellular milieu of 
the adult brain, these common matrix elements are expressed in localized regions of the 
developing brain (Rutka et al., 1988; Ruoslahti, 1996). Therefore, with respect to the neural 
ECM, oncology recapitulates ontogeny. 
While the expression of unique ECM components in glioma cells is detailed above, glioma 
cells also modulate the expression of cell-surface receptors, which enhances their ability to 
interact within the neural environment. One class of surface receptors altered in glioma 
tumors are cell-cell adhesion molecules, which comprise several different molecular families 
of receptors (Barami et al., 2006).  Cell-cell adhesion molecules play important roles in 
regulating cell motility through interactions with ECM components and other cell adhesion 
molecules. Several signal transduction pathways directly regulate the cellular repertoire of 
adhesion molecules to dictate both extracellular and intercellular interactions. The inverse is 
also true, as activated cell adhesion molecules are capable of modulating intracellular 
signaling to influence cellular processes like adhesion, motility and even cell fate (Cavallaro 
& Christofori, 2004). In terms of glioma tumor pathophysiology, the activation of cell 
adhesion molecules are equally as important as the activation of signal transduction 
cascades, as signaling from both modulate tumor cell behavior. 
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In glioma tumors, ECM receptors like tenascin, integrins and certain cell-cell adhesion 
molecules mediate interactions between the extracellular environment and surface of the cell 
to influence cell behavior by modulating intracellular signaling. Tenascins are large 
molecular weight cell-surface glycoproteins that can function as receptors for proteoglycans 
including the lectican family members. Importantly, tenascin family members are also 
overexpressed in glioma specimens and have been linked to tumor cell invasion and 
angiogenesis (Aspberg et al., 1995; 1997; Hirata et al., 2009; Leins et al., 2003; Zagzag et al., 
2002). While tenascin can function as receptors for proteoglycans, they are also secreted 
proteins that depend in part on interactions with cell-adhesion molecules at the cellular 
plasma membrane to confer their functionality. Tenascin has been shown to interact with 
integrins, which are integral membrane cell surface receptors involved in cell-ECM 
interactions (Deryugina & Bourdon, 1996; Giese et al., 1996). In addition to binding tenascin, 
integrins also bind fibrillar proteins like laminin and fibronectin that are expressed in the 
tumoral extracellular environment (Knott et al., 1998; Ohnishi et al., 1998). The interaction of 
integrins with both tenascin and fibrillar matrix proteins in the tumor microenvironment 
have been shown to enhance the motility and invasive properties of glioma tumor cells 
(Deryugina & Bourdon, 1996; Hirata et al., 2009).  Upon binding to ECM ligands, integrins 
effectively transduce changes in the ECM into alterations in cellular behavior by activating 
signal transduction cascades that reorganize components of the cellular cytoskeleton to 
facilitate cell movement (D'Abaco & Kaye, 2007). 
Cell-cell and cell-ECM interactions of glioma tumor cells are also critically regulated by 
extracellular proteases. Tumor cell invasion is strongly influenced by the proteolytic 
cleavage of ECM components and certain cell adhesion molecules, as proteolysis creates an 
extracellular environment permissive to cellular migration by facilitating the turnover of 
ECM components (Rao, 2003 and section 2.2). The complex interplay between HA, 
proteoglycans and their receptors, integrins, cell-cell adhesion molecules, and proteases 
present within the tumor stroma facilitate glioma invasion through the normally inhibitory 
extracellular environment of the mature CNS. 
The restricted invasive profile of gliomas suggests that nervous system-specific proteins 
expressed only by neoplastic cells that are phenotypically glial may be key mediators of 
glioma invasion. Thus, making components of the neural ECM and adhesion molecules with 
expressions that are restricted or specifically enriched within the CNS appealing avenues of 
research for future therapeutic targets. Proteins with CNS enriched or specific expression 
that are overexpressed in human glioma tumors include but are not limited to B/b  
(Jaworski et al., 1996), specific isoforms of versican (Dours-Zimmermann & Zimmermann, 
1994; Paulus et al., 1996), and RPTP ( Muller et al., 2003). Inhibiting molecular mechanisms 
leading to glioma tumor cell invasion is critical to effectively curing these deadly tumors. 
Furthermore, the identification of pro-invasive mediators that are both nervous system and 
tumor-specific would create molecular targets for novel therapies with reduced off-target 
effects, thus limiting the potential of inducing broad systemic toxicity. 
3.2 Proteolytic degradation of the neural extracellular matrix is critically involved in 
tumor cell invasion 
In order for glioma tumor cells to invade the normal surrounding brain tissue, tumor cells 
must both interact with the ECM of the adult CNS, which is accomplished through the 
synthesis of tumor-produced ECM, altered receptor expression, and proteolytic cleavage. 
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Several different families of proteases are overexpressed in gliomas including MMPs, 
ADAMTS, serine, cysteine, and asparate and play important roles in mediating glioma 
tumor invasion and progression (Levicar et al., 2003). Proteases expressed by glioma tumor 
cells degrade the mature inhibitory ECM of the adult CNS and the glioma-expressed matrix 
elements. Proteolytic activity allows for turnover of ECM components and facilitates 
invasion by dynamically remodeling the extracellular environment to become more 
permissive to cellular reorganization (Yamamoto et al., 2002). Therefore, glioma tumor cell 
invasion is dependent on both the overproduction and proteolytic cleavage of ECM 
components. The importance of ECM cleavage is highlighted by previous work on B/b that 
showed both its overexpression and proteolytic processing are required for increased 
glioma cell invasion, as a mutated non-cleavable form of B/b did not enhance cell invasion 
(Viapiano et al., 2008). In addition to mediating aspects of invasion, proteases belonging to 
these families have also been linked to increases in glioma tumor cell proliferation and 
angiogenesis (Lakka et al., 2005). The regulation of proteolytic activity in gliomas is complex 
with each level of regulation representing a facet for potential therapeutic intervention. 
Proteolytic activity can be regulated at different levels resulting from either an increase in 
transcription or activation, as most proteases require cleavage of an inactive pro-peptide 
form for enzymatic activity. The proteolytic activity of both ADAMTS and MMP family 
members are naturally inhibited by endogenously occurring proteins belonging to the 
Tissue Inhibitor of Metalloproteinases (TIMP) family (Brew & Nagase, 2010). In several 
disease pathologies including gliomas, an imbalance between protease activity and TIMP 
expression accounts for elevated levels of proteolysis in the pathogenic state (Kachra et al., 
1999). Therefore, both the overexpression and activation of ADAMTS and MMP proteases 
along with the TIMP family of endogenous protease inhibitors are attractive therapeutic 
targets for their role as molecular determinants of glioma tumor cell invasion. 
The functional role of proteases in glioma tumor pathology is exemplified by the MMP 
family members, which have important roles in the progression of most neoplasms and 
happen to be the most well characterized protease family in glioma tumors (Levicar et al., 
2003).  The MMPs comprise a large family of matrix peptidases that are classified on the 
basis of their preferred substrate, for which there is considerable overlap between family 
members (Rao, 2003). MMPs are produced both by glioma tumor cells and endothelial cells 
that comprise the tumor vasculature (Raithatha et al., 2000). Two of the most well 
documented MMPs in glioma are MMP-2 and MMP-9, also known as gelatinase-A and 
gelatinase-B, respectively. Their expressions are increased in glioma tumors and have been 
correlated with increased glioma tumor cell invasiveness (Nakagawa et al., 1996; Wild-Bode 
et al., 2001; Levicar et al., 2003). Additionally, the expression of these proteases correlated 
with the degree of glioma tumor malignancy, as increased levels of MMP-2 and MMP-9 
were observed in high-grade glioma tumors relative to low-grade (Wang et al., 2003). 
Knocking down the expression of MMP-9 in an invasive glioma cell line resulted in 
decreased tumor cell infiltration into the surrounding brain tissue and decreased cell 
motility and invasion in vitro (Zhao et al., 2010). Upstream signaling molecules that regulate 
the expressions of MMP-2 and MMP-9 are also potential therapeutic targets of interest. 
Previous studies have shown that JNK and ERK signaling positively regulate the expression 
of MMP-9, and interfering with either of these pathways reduced the invasiveness of a 
glioma cell line (Lakka et al., 2000). 
Based on elevated MMP expression, activation, and function in glioma tumor invasion and 
progression, a considerable amount of investigation into using chemical inhibitors of MMPs 
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as therapeutic agents to reduce the pathogenesis of glioma tumors has ensued. Clinical trials 
using a broad MMP inhibitor failed to improve patient prognosis and caused systemic 
toxicity in patients, in the form of joint pain (Groves et al., 2006; Levin et al., 2006). The 
expression of MMPs in cartilage and their role in maintaining normal cartilage and joint 
physiology presumably accounted for these deleterious affects (Itoh et al., 2002). Findings 
from these studies suggest that the function of MMPs in both the pathogenesis of glioma 
tumors and its role in normal physiology are more complex than is currently understood. 
Additionally, these findings suggest that other proteases that play less of a role in 
maintaining normal physiology while still mediating aspects of glioma tumor invasion may 
be better candidates for therapeutic intervention. 
Specific ADAMTS family members exemplify proteases that are attractive therapeutic 
candidates on the basis of their contribution to glioma tumor invasion and disease 
progression and seemingly less critical role in maintaining normal physiology (Majumdar et 
al., 2007; Nakada et al., 2005). Interestingly, the expression and activity of ADAMTS-4 and 5 
are enriched in human glioma tumors relative to normal adult brain (Held-Feindt et al., 
2006), with the expression of ADAMTS-5 being the most significantly upregulated in glioma 
(Nakada et al., 2005). Their expression has been shown to contribute significantly to glioma 
invasion and disease progression, which is mediated by their ability to cleave components 
of the extracellular matrix such as B/b (Matthews et al., 2000; Nakada et al., 2005) and 
versican (Sandy et al., 2001). Therefore, the preferred substrates of ADAMTS-4 and 5 in the 
CNS are presumably more restricted than other proteases, favoring extracellular matrix 
components that are enriched in glioma tumors with CNS-specific expression. Importantly, 
ADAMTS-4 and 5 are seemingly dispensable for normal physiology, as double knockout 
animals exhibited no deleterious affects and were indistinguishable from controls 
(Majumdar et al., 2007). Thus suggesting that targeting the systemic expression of 
ADAMTS-4 and 5 would have fewer off-target effects. 
The pro-invasive contribution of ADAMTS-4 and 5 to proteolytic cleavage is further 
enhanced by recent work that described a novel molecular mechanism between these 
proteases and glioma produced ECM to facilitate glioma cell invasion. Importantly, the 
proteolytic cleavage of B/b by ADAMTS-4 and 5 was found to reveal cryptic binding sites 
on B/b to promote its motogenic effects (Hu et al., 2008).  The proteolytic cleavage 
fragments of B/b were shown to effectively bind to fibronectin, which caused the 
polymerization of fibronectin microfibrils surrounding the surface of the cell and increased 
glioma tumor cell adhesion and motility. The interaction between B/b and fibronectin was 
only observed for the N-terminal proteolytic cleavage fragment of B/b and not for the full-
length form of the protein. B/b mediated increases in cell adhesion and motility were found 
to be dependent on both its proteolytic processing and interaction with fibronectin, as a 
forced reduction in fibronectin expression attenuated the motogenic effects of B/b (Hu et al., 
2008). In the adult brain the proposed mechanisms would be inconceivable given the lack of 
fibronectin expression, however the tumor-specific expression of it by glioma cells enables 
mechanisms of B/b-mediated cell motility to proceed in a nervous system specific manner 
that is critically dependent on proteolysis. 
4. Tumoral cellular interactions within the extracellular space of the CNS 
4.1 Extracellular interactions mediate tumor cell invasion 
Dispersion of cells within the brain requires direct interactions of the tumor cells with the 
surrounding environment and ultimately activation of signaling pathways downstream of 
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these interactions. In gliomas, cellular interactions within the environment are mediated by 
a number of key receptor systems. 
The most well-studied matrix receptors are the Integrins. Integrins are a family of cell 
surface receptors that communicate changes in the extracellular environment to intracellular 
mediators by activating several signal transduction cascades. Integrins are comprised of a 
large family of heterodimeric transmembrane glycoproteins, the dimerization of different 
integrin subunits dictates the specificity and preference of these receptors for particular 
ECM components (Akiyama, 1996). In gliomas the tumor-specific overexpression of 
integrins V3 and V5 have been described along with their localization along blood 
vessels and on the surface of glioma tumor cells, suggesting they play a role in angiogenesis 
and cell motility (Bello et al., 2001; D'Abaco & Kaye, 2007; Gladson, 1996; Schnell et al., 
2008). Cilengitide, a synthetic RGD pentapeptide that acts as an inhibitor of integrins V3 
and V5, has shown promising clinical results and is now being evaluated in Phase III 
clinical trials (Nabors et al., 2007, Tabatabai et al., 2010). 
In addition to integrins, HA binding proteins like the lecticans mediate the interaction 
between the extracellular environment and glioma tumor cells. BEHAB/ brevican (B/b), a 
nervous-system specific lectican family member, is significantly upregulated in human 
glioma specimens relative to normal brain (Jaworski et al., 1996). The expression of B/b is 
limited to invasive tumors of glial phenotype within the intracranial environment, thus 
mirroring the restricted invasive profile of gliomas (Jaworski et al., 1996). Of importance, 
previous studies have shown that increased B/b expression led to elevated tumor cell 
invasion and tumor aggressiveness in animal models (Nutt et al., 2001b). Likewise, RNAi 
mediated knockdown of B/b decreased tumor cell invasion and reduces tumor 
aggressiveness leading to prolonged survival of animal models (RTM, unpublished 
findings).  It has been determined that the upregulation of B/b expression in gliomas occurs 
at both the level of transcription and translation, suggesting that a glioma-specific signaling 
pathway is responsible for regulating increased B/b expression (Gary et al., 2000; Viapiano 
et al., 2005). These unknown regulatory mechanisms represent potentially valuable 
therapeutic candidates, as they presumably would be regulators of glioma cell motility with 
nervous system and tumor specific expression. 
Understanding the function of B/b overexpression is challenging due to the presence of 
several post-translationally modified protein isoforms, all of which are present in glioma 
specimens at levels far greater than normal brain. These include the full-length secreted 
protein, proteolytic cleavage fragments, and tumor-specific isoforms B/bsia and B/bg 
(Viapiano et al., 2003, 2005). B/bsia is an over sialidated form of B/b, exhibiting typical post-
translational increases in sialic acid modifications observed in many neoplasms (Viapiano et 
al., 2005). B/bg is a hypoglycosylated full-length protein isoform resulting from decreased 
decoration of the full-length core protein with O-linked oligosaccharides. Interestingly, 
B/bg is bound to the cellular plasma membrane by unknown mechansisms that are 
distinct from those tethering other B/b isoforms to the cellular surface. While the exact 
contribution of the B/bg isoform to B/b-mediated increases in cell motility and invasion is 
undetermined, B/bg is the most highly upregulated isoform of B/b present in human and 
rodent glioma tumor specimens and its localization to the cellular plasma membrane is 
suggestive of an important pathogenic function (Viapiano et al., 2003, 2005). Both the tumor-
specific expression and cellular localization of B/bg make it an attractive therapeutic target 
for either its participation in B/b-mediated motogenic effects or for targeted drug delivery 
methods. 
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B/b also undergoes proteolytic processing by the ADAMTS-4 and 5 family members 
resulting in cleavage of the 150kDa full-length protein into a 50kDa and 100kDa N and C-
terminal cleavage fragments, respectively (Matthews et al., 2000, Viapiano, 2005). The 
proteolytic processing of B/b is required for B/b-mediated increases in tumor cell motility 
as discussed previously (Viapiano et al., 2008; Hu et al., 2008). The overexpression and 
proteolytic processing of B/b was found to activate Epidermal Growth Factor Receptor 
(EGFR) signaling resulting in elevated levels of fibronectin expression which was assembled 
into microfibrils at the cells surface in a B/b-dependent manner. Increased expression of 
integrin 3 and N-cadherin were also observed in response to B/b overexpression and these 
affects were found to be specific to glioma cells cultured in the presence of fibronectin (Hu et 
al., 2008). The summation of findings on B/b expression and function in glioma suggests 
that targeting B/b at the levels of transcriptional regulation, post-translational 
modifications, and proteolytic processing all represent novel avenues that could potentially 
reduce glioma tumor cell invasion. 
Versican, another member of the lectican family of CSPGs, is also highly expressed in 
glioma specimens along with other systemic cancer types like breast cancer. In human 
glioma specimens and cell lines many different spice variants of versican are overxpressed 
including both the nervous system-specific V2 isoform and the more broadly expressed 
V0/V1 isoforms (Arslan et al., 2007; Dours-Zimmerman & Zimmerman, 1994; Paulus et al., 
1996). The expression of versican in glioma has been linked to increased tumor size, 
angiogenesis and glioma cell motility (Zheng et al., 2004). Protein isoforms containing the 
G3 domain of versican, which consists of the C-terminal domains common to lectican family 
members, has been shown to be abundantly expressed in glioma specimens and play a role 
in regulating tumor growth and angiogenesis. Overexpression of the versican G3 domain in 
glioma cells resulted in tumors of increased size and enhanced vasculature in animal 
xenographs compared to controls. Versican G3 conditioned media was found to enhance 
endothelial cell adhesion, proliferation and migration. Furthermore, the overexpression of 
versican G3 was found to increase the expression of fibronectin and Vascular Endothelial 
Growth Factor (VEGF). The elevated expression levels of fibronectin and VEGF formed a 
complex with versican G3 that could be co-immunoprecipitated, the additive effects of all 
three components of the complex – versican, fibronectin and VEGF to endothelial cells 
exacerbated the effect that either component alone or in pairs had on the adhesion, 
proliferation and migration of endothelial cells, substantially increasing it (Zheng et al., 
2004). More recently, the ability of transforming growth factor - 2 (TGF- 2) was shown to 
have an enhancing effect on the expression of versican V0/V1 isoforms. Furthermore, the 
addition of TGF- 2 exerted a motogenic effect on glioma cells that was partially mediated 
by increased V0/V1 expression (Arslan et al., 2007). 
The overexpression of versican VI was found to induce neuronal differentiation of PC12 
cells, an immortal cell line used to model neural precursor cells, through an integrin-
dependent mechanism resulting from activation of EGFR and downstream signaling 
through ERK (Wu et al., 2004). While a versican-mediated affect on EGFR signaling in 
glioma tumor cells remains unexplored, mechanisms leading to B/b-mediated increases in 
cell invasion closely resemble those described for versican (Hu et al., 2008). Therefore it is 
interesting to speculate that overexpression of certain lecticans (B/b or versican or perhaps 
neurocan) by glioma tumor cells may be sufficient to mediate tumor cell motility by utilizing 
similar pathomechanisms stemming from increased fibronectin expression, EGFR activation, 
and integrin expression. Versican also undergoes proteolytic processing in glioma, however 
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the function of this cleavage in the pathogenesis of glioma remains unexplored (Westling et 
al., 2004). Versican represents an attractive therapeutic target for its functional role in glioma 
tumor growth, angiogenesis and cell motility. 
The pro-invasive function of proteoglycans like B/b and versican may be, in-part, mediated 
by their interaction with cell-surface receptors, like tenascins. Tenascins are large secreted 
extracellular glycoproteins that bind to the cell surface through interactions with integrins 
(Bourdon & Ruoslahti, 1989). Tenascin-C and tenasin-R have been shown to bind to 
proteoglycans with high affinity to bridge the molecular gap between secreted 
proteoglycans in the extracellular space and the cellular plasma membrane (Aspberg et al., 
1995, 1997; Barnea et al., 1994; Milev et al., 1997). Pioneering studies demonstrated that 
tenascin proteins are expressed by glioma cell lines in vitro and are present at higher levels 
in glioma specimens relative to normal brain tissue (Ventimiglia et al., 1992; Zagzag et al., 
1995). Additionally, the use of tenascin as an immobilized protein substrate was found to 
enhance human glioma cell migration through an 21 integrin-dependent mechanism 
(Deryugina and Bourdon, 1996). 
Subsequent to these studies, four tenascin family members were identified including 
tenascin-C, R, W, and X, all of which have been implemented in several physiological and 
pathophysiological functions including embryonic development, wound healing and are 
present in several solid tumor types. Tenascin-R expression is restricted to the CNS, while 
other tenascin family members are ubiquitously expressed (Hirata et al., 2009). The 
expressions of both tenascin-C and W have been identified surrounding tumor vasculature 
in glioma specimens, however tenascin-C is the best studied in glioma for its role in 
enhancing tumor cell invasion. In GBM patients, increased expression of tenascin-C is 
correlated with an adverse prognosis. Moreover, the endogenous expression of tenascin-C 
in GBM tumor cells was found to enhance cell invasion and correlated with reactive changes 
in the normal brain tissue surrounding GBM tumors in patients (Hirata et al., 2009).  Like 
several ECM components, tenascin-C-mediated increases in glioma cell invasion are 
dependent on proteolytic processing. In glioma tumor cells tenascin-C is cleaved 
predominantly by MMP-12, and the inhibition of MMP-12 activity attenuated tenascin-C 
mediated glioma cell invasion (Sarkar et al., 2006). The tumor-specific upregulation of 
tenascin-C along with its pro-invasive function make it an attractive therapeutic target for 
anti-invasive therapies and it has shown some promise in clinical trials (Riva et al., 1999a ,b). 
Another proteoglycan that has also been shown to interact with tenascins and is 
upregulated in glioma specimens is (RPTP)/ Phosphacan (Adamsky et al., 2001; Muller et 
al., 2003). RPTP is a transmembrane receptor tyrosine kinase phosphatase, which like the 
lecticans is also a CSPG bearing extensive decoration with CS-GAG chains. However unlike 
the lecticans, RPTP lacks an HA binding domain and does not interact directly with the HA 
scaffold of the neural extracellular space. The N-terminal protein domains of RPTP, are 
comprised of a carbonic anhydrase-like domain and a fibronectin type III-like domain. The 
central domain, which contains the transmembrane domain bears CS-GAG moieties that 
modulate the interaction of RPTP with several of its ligands, and the C-terminal protein 
domains are made up of two intracellular phosphatase domains (Peles et al., 1998). 
While the protein structures of RPTP and lectican CSPGs are highly divergent, both RPTP, 
neurocan and versican have several common ligands including tenascins, NCAM, L1-CAM, 
contactin, and Transient Axonal Glycoprotein 1 (TAG-1/ axonin-1) (Peles et al., 1998; Rauch 
et al., 2001). RPTP is encoded from the PTPRZ1 gene and has four known isoforms 
resulting from alternative splicing. These include the full-length receptor form RPTP, a 
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short-receptor form, a secreted form, phosphacan, which lacks the transmembrane regions 
and intracellular phosphatase domains, and a truncated secreted form, PSI (Phosphacan 
Short Isoform) (Garwood et al., 2003). RPTP expression is enriched in the CNS and is 
upregulated in human glioma tumors along with its soluble ligand pleiotrophin (PTN)/ HB-
GAM relative to normal brain (Muller et al., 2003). Upon binding to PTN, RPTP receptors 
cluster resulting in the inactivation of endogenous phosphatase activity, which leads to 
increased phosphorylation of downstream effector molecules like -catenin. 
Phosphorylation of -catenin stabilizes the protein and facilitates canonical -
catenin/cadherin and WNT pathway signaling, which have implications in cell motility, 
proliferation and cell fate decisions (Meng et al., 2000). In glioma tumor cells, RNAi 
mediated knockdown of RPTP in a human glioma cell line reduced the size of engrafted 
tumors in rodent models and decreased the proliferation rate of tumor cells in vitro. The 
reduction in RPTP expression also decreased PTN-mediated increases in cell proliferation 
and motility (Ulbricht et al., 2006). A similar study also found that RPTP knockdown cells 
had reduced motility on a PTN-immobilized substrate but did not see any affects on cell 
proliferation (Muller et al., 2003). Given that RPTP is upregulated in human glioma tumors, 
localized to the cellular surface and regulates complex cellular behaviors that contribute to 
glioma pathogenesis, RPTP is a prime candidate target for future glioma therapies. Both 
cell-ECM and cell-cell adhesion molecules play critical roles in translating changes in the 
extracellular environment to alterations in the cellular cytoskeleton 
4.2 Intercellular interactions mediate tumor cell invasion 
While interactions with the ECM mediate aspects of glioma invasion, this process also 
involves interactions between both adjacent tumor cells and tumor cells with normal cells 
within the CNS, which are typically mediated by cell adhesion molecules.  
Cell-cell adhesion molecules typically exhibit homophilic binding to mediate intercellular 
interactions with adjacent cells expressing the same cell-adhesion molecule but have also 
been shown to interact with constituents of the ECM through heterophilic binding (Hinsby 
et al., 2004). In addition to mediating intercellular adhesion, molecules like the 
Immunoglobulin (Ig) superfamily of Cell Adhesion Molecules (CAMs) and cadherins also 
modulate signal transduction cascades to translate extracellular interactions into 
intracellular changes by impinging on the activation of receptor tyrosine kinases, molecular 
components of the WNT signaling cascade, and RhoGTPases  (Cavallaro & Christofori, 
2004). The functional roles of cell-cell adhesion molecules in glioma invasion are complex, as 
either their ability to enhance or inhibit glioma cell motility is dependent on both post-
translational modifications and interactions with specific ligands. Neuronal- cadherin (N-
cadherin) provides an exemplary model of this, as the degree of organization and 
maturation of N-cadherin cell-cell junctions impacts the migratory capacity of glioma cells, 
wherein more organized cell-cell junctions inhibit cell motility. However, the organization 
and maturation of cell-cell junctions depends critically on the presence or absence of specific 
ECM ligands (Perego et al., 2002). As a result of these complex biochemical underpinnings, 
the expressions and functions of specific cell-cell adhesion molecules have been 
differentially reported, most likely resulting from context-specific interactions that have yet 
to be fully understood. 
The Ig-CAMs play important roles in cell migration and invasion in several physiological 
and pathophysiological functions including development, wound healing and cancer 
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metastasis. The Neural Cell Adhesion Molecule (NCAM) has a complex role in mediating 
aspects of glioma tumor cell adhesion, migration and invasion. The overexpression of 
NCAM was found to decrease glioma tumor cell motility through non-homophilic 
interactions by blocking binding of glioma tumor cells to extracellular substrates. Both the 
intracellular and extracellular portions of the NCAM receptor independently were found to 
block glioma cell motility, for which the extracellular Ig domains were determined to be 
critical. Therefore the attenuation of motility by the overexpression of the NCAM 
extracellular domain was believed to be due to the heterophilic interaction of the Ig domains 
with a constituent of the ECM thereby competing off endogenous motogenic receptors (Prag 
et al., 2002). More recently, a loss of NCAM expression in gliomas of increasing WHO grade 
was determined, suggesting that the negative regulation of NCAM is involved in glioma 
progression.  The loss of NCAM expression was also correlated with more diffuse brain-
tumor interfaces (Duenisch et al. 2011). 
Interestingly, NCAM is the major substrate for Poly Sialic Acid (PSA) modifications 
resulting in PSA-NCAM. The overexpression of enzymes that attach the PSA moiety 
resulted in increased invasion of intracranial grafts compared to PSA negative NCAM alone. 
Furthermore, increased tumor cell invasion was observed for both PSA positive and 
negative NCAM glioma tumor cells in NCAM knockout mice, lacking NCAM expression in 
the nervous system environment, suggesting that the PSA modification serves to attenuate 
NCAM homophilic interactions to mediate increased glioma cell invasion (Suzuki et al., 
2005). Furthermore, the expression of PSA-NCAM was found to correlate with an adverse 
progonisis for GBM patients (Amoureux et al. 2010). Therefore the negative regulation of 
NCAM homophilic binding resulting from either a decrease in NCAM expression or the 
glycosylation of NCAM to yield PSA-NCAM enhances glioma tumor cell motility and 
invasion. 
The cadherin family members are calcium dependent cell-cell adhesion molecules that 
interact with catenins to signal changes in the actin cyctoskleton. Studies have demonstrated 
that N-cadherin is expressed by glioma cells, however conflicting evidence exists as to the 
function of this expression (Barami et al., 2006).  Regardless of these conflicting reports, it 
has been determined that N-cadherin proteolytic cleavage by the ADAMTS-related protease 
ADAM-10 is a key mediator of GBM cell motility (Kohutek et al., 2009). Both epithelial-
cadherin (E-cadherin) and N-cadherin have been found to play important roles in mediating 
glioma tumor cell motility with the CNS, but recent studies suggest that elevated E-cadherin 
levels at the expense of N-cadherin in glioma cell lines has been associated with increased 
tumor aggressiveness (Lewis-Tuffin et al. 2010). Further investigation into the complex 
pathomechanisms of cell-cell adhesion molecules and their heterophilic interactions with 
ligands of the ECM in the context of glioma cell dissemination is important to 
understanding the macroscopic contribution of the neural extracellular environment to 
glioma invasion and progression. 
5. Glioma tumor initiating cells and the neural ECM 
In addition to the ability of glioma tumor cells to invade the normal surrounding brain 
tissue, another major therapeutic obstacle is the presence of a tumor stem cell-like 
population of cells that reside within the solid tumor mass. This small cellular 
subpopulation is resistant to radiotherapy and capable of repopulating the original parental 
tumor leading to tumor recurrence and disease progression (Chalmers, 2007). Interestingly, 
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constituents of the neural ECM and cell-cell adhesion molecules are also implicated in the 
pathomechanisms of this small but lethal cellular subpopulation. 
5.1 Cancer initiating cells are present in human glioma tumors 
Cancer initiating cells (CICs) also called “cancer stem cells” were initially identified in 
human leukemia, and have since been described in several solid tumor types including 
gliomas (Galli et al., 2004; Singh et al., 2003, 2004 ). CICs were first isolated from human 
glioma tumors by culturing tumor cells in a media composition that closely resembles 
neural stem cell media, comprised of a serum-free base with Epidermal Growth Factor 
(EGF) and basic Fibroblast Growth Factor (bFGF). The resulting GIC population exhibited 
several distinct phenotypic characteristics from other glioma tumor cells, which serve as 
criterion to operationally define GICs and are: 1. the ability to self-renew, 2.  multipotency – 
the ability to differentiate into every cellular subclass present within the CNS, and 3. the ability 
to phenotypically recapitulate the original parental tumor upon orthotopic transplantation 
(Galli et al., 2004; Singh et al., 2004). The presence of a GIC subpopulation within human 
glioma tumors suggests a complex intratumoral heterogeneity, wherein GICs are molecularly 
and phenotypically distinguishable from other glioma tumor cells. Recent evidence suggests 
that GICs are highly refractory to current adjuvant therapeutic treatments resulting from their 
slow progression through the cell cycle and upregulation of DNA repair mechanisms (Bao et 
al., 2006).  According to the controversial “cancer stem cell hypothesis”, CICs maintain stem-
like characteristics that fuel the growth of the tumor by giving rise to all other tumor cell types 
through a process that closely resembles normal cellular differentiation and effective 
eradication of tumors requires the ablation of the CIC population. 
While a significant amount of research supports the role of GICs in the pathophysiology of 
gliomas and the resemblance of GICs to their glial and neural stem cells counterparts, the 
utility of GICs as a model for primary glioma tumors is unparalleled. Initial evidence 
suggested that glioma tumor cells cultured in serum free media with EGF and bFGF more 
closely resembled original parental tumors both molecularly and phenotypically than serum 
cultured cell lines (Lee et al., 2006). These findings were seminal as they suggested, 
regardless of the controversy surrounding “cancer stem cells”, that GICs are likely a more 
representative model of primary glioma tumors than traditional serum cultured cell lines.  
GICs are highly tumorigenic and a significant amount of research has gone into identifying 
molecular markers of the most highly tumorigenic subpopulation. Although controversial, 
CD133 expression has been correlated to increased GIC tumorigenicity (Campos & Herold-
Mende, 2011). While both CD133+ and CD133- GIC cells have been found to be highly 
tumorigenic, recent evidence suggests that two subpopulations of CD133- cells are present 
within glioma tumors; one which is tumorigenic and gives rise to CD133+ cells and another 
that is not (Chen et al., 2010). Thus offering a solution to the long-standing conundrum 
surrounding the correlation between CD133 expression and tumorigenicity. 
5.2 Neural extracellular matrix expression denotes subtypes of gliomas and glioma 
initiating cells 
High-grade gliomas, glioblastoma muliforme, were so named for the considerable intra as 
well as intertumoral heterogeneity observed across individual glioma tumors. In efforts to 
better characterize glioma subtypes and begin an investigation into the value of 
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individualized patient-tailored therapies, molecular subclasses of hundreds of primary 
glioma tumors were evaluated on the basis of their gene expression profile signatures. In 
this seminal study by Phillips and colleagues, three molecular subpopulations of glioma 
tumors were identified proneural, proliferative, and mesenchymal (Phillips et al., 2006). The 
identification of different molecular subclasses of glioma tumors set the stage for an 
investigation into the presence of distinct molecular subtypes of GICs. Gunther and 
colleagues created GIC cell lines from nine human GBM tumors and their molecular gene 
profile signatures determined (Gunther et al., 2008). Interestingly, two distinct molecular 
subpopulations of GICs emerged as separate clusters, cluster-1 and cluster-2. GIC cell-lines 
belonging to cluster-1 cells grew as spheres, had increased multipotency, expressed high 
levels of CD133, and created highly invasive intracranial tumors. In contrast, cluster-2 GICs 
grew as adherent or semi-adherent cultures, were restricted in cell fate, had little or no 
expression of CD133 expression, and exhibited low tumorigenicity and resulted in poorly 
invasive tumors in vivo (Gunther et al., 2008). 
Lottaz and colleagues determined that cluster-1 GICs were most similar to proneural GBM 
tumors, while cluster-2 GICs were closely related to the mesenchymal GBM subtype (Lottaz 
et al., 2010). In accordance with these findings, the expression of BCAN was specifically 
enriched in the proneural GBM subtype and cluster-1 GICs which were found to be more 
highly tumorigenic than cluster-2 GICs and correlated with increased CD133 expression 
(Gunther et al., 2008). Work from our own lab has replicated these findings demonstrating 
that B/b is highly expressed by GICs with a phenotype similar to that described for cluster-1 
cells. While the exact function of B/b expression by GICs is currently under investigation, 
the unique pathophysiological properties of GICs suggest that B/b may have broader 
functionality than observed in terminally differentiated glioma tumor cells. Likewise the 
restricted expression of CD44 was also identified in cluster-2 GICs along with integrins 1 
and 5 (Gunther et al., 2008), again suggesting that differential expression of neural ECM 
components may contribute to differences in the pathophysiology of distinct molecular 
subclasses of GICs. The identification of neural ECM expression by GICs suggests that 
molecular constituents of the neural ECM could be employed as therapeutic targets that also 
impinge on the highly tumorigenic GIC subpopulation to reduce tumor recurrence and 
improve patient prognosis. Further research is needed to characterize the function of neural 
ECM components and cell adhesion molecules in the GIC population to fully evaluate  
the efficacy of targeting their expression to improve the prognosis of patients with GBM 
tumors. 
5.3 The neural extracellular matrix and glioma initiating cells 
While the function of neural ECM expression by GICs remains largely unknown, GICs are 
phenotypically and molecularly similar to normal neural stem cells (NSCs) (Rebetz et al., 
2008). Suggesting that the microenvironment, or stem cell-like niche, surrounding GICs may 
share several parallels with the composition and function of the microenvironment 
surrounding NSCs during neurodevelopment and in the adult brain (Denysenko et al., 
2010). In support of this hypothesis, the stem-cell niche that comprises the normal NSC 
microenvironment contains elevated levels of several ECM components whose expressions 
are enriched in GICs and gliomas including but not limited to laminin (Shen et al., 2008) and 
tenascin-C (Garcion et al., 2004). Moreover, NSCs themselves have been shown to express 
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the same neural ECM constituents expressed by GICs including the lectican family members 
(Kabos et al., 2004), phosphacan/ RPTP (Abaskharoun et al., 2010b, a), tenascin-C 
(Abaskharoun et al., 2010a), integrin 61 (Shen et al., 2008). 
Of importance, both GICs and NSCs reside in highly vascularized niches and are often 
localized surrounding blood vessels (Gilbertson and Rich, 2007; Shen et al., 2008). Normal 
NSCs reside in the subventricular zone (SVZ) of the developing brain, which is inherently 
highly vascularized (Shen et al., 2008). In the adult SVZ, the association between endothelial 
cells comprising the vasculature of the stem cell microenvironment and NSCs are mediated 
by an interaction between laminin on endothelial cells and a major laminin binding integrin, 
61. The inhibition of integrin 6 was found to disrupt the association between endothelial 
cells and NSCs and caused a significant decline in NSC proliferation. These findings 
highlight the functional significance of a close association between vascular endothelial cells 
and stem cells in maintaining their stem cell-like properties (Shen et al., 2008). Similar 
findings have also been reported for GICs, which further supports the hypothesis that the 
composition of the microenvironment surrounding GICs closely mirrors that for NSCs and 
as a result may have common functions in maintaining the stem cell-like state. 
In gliomas the vasculature that comprises the GIC microenvironment typically arises de 
novo as part of tumorigenesis, or as recent evidence suggests from the differentiation of 
GICs into endothelial cells (Ricci-Vitiani et al., 2010). The close association between tumor 
vasculature endothelial cells and GICs was found to be imperative for maintaining the stem 
cell-like phenotype of this cellular population (Williams et al., 2010). Moreover, the 
expression of integrin 6 was identified as a marker of GICs residing within the 
perivascular niche. The inhibition of this cell adhesion molecule was found to block the 
interaction between laminin on vascular endothelial cells and GICs, which subsequently 
impeded GIC self-renewal, proliferation, and tumorigenic capacity (Lathia et al., 2010). 
These studies suggest that targeting the microenvironment, or stem cell-like niche, 
surrounding GICs may be a therapeutically advantageous approach to force the GIC 
subpopulation out of its stem cell-like state and to become subsequently more responsive to 
adjuvant therapies. Therefore, the components that comprise this unique stem cell-like 
microenvironment surrounding GICs represent attractive therapeutic candidates to inhibit 
tumor recurrence. 
6. Conclusion 
The ability of glioma cells to interact with and invade into the extracellular environment 
within the CNS is a critical contributor to the pathogenesis of these tumors and poor patient 
prognosis. Gliomas modulate their surrounding environment through the expression of 
unique matrix elements and cleavage of the normal matrix. In addition, they alter 
expression of cell surface receptors to mediate unique interactions within this neural 
environment. Recently, work suggests that GICs also employ a similar strategy to surround 
themselves with a neurogenic microenvironment. Therefore, therapeutic interventions that 
interfere with the expressions of neural ECM constituents, cell surface receptors, and cell 
adhesion molecules may represent ideal targets both to impede glioma invasion and also the 
tumorigenic qualities of GICs, thus targeting two major contributors to tumor recurrence 
and disease progression. Further work understanding the role of the ECM in glioma tumor 
pathogenesis is critical to develop better strategies for treatment of patients with gliomas. 
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